News Digest / Ticker: VKTX

Ticker: VKTX

02:57am, Wednesday, Aug 20, 2025

Viking (VKTX) Plunges 37% After VK2735 Delivers 12.2% Weight Loss - 28% Discontinuation Sparks Concern

Viking Therapeutics (VKTX) plunged ~37% after Phase 2 VENTURE showed VK2735 met its primary endpoint-up to 12.2% weight loss at 13 weeks-but a 28% discontinuation rate and GI side effects spurred adoption worries; Eli Lilly (LLY) edged up.

06:02pm, Wednesday, Jul 23, 2025

Viking Therapeutics Reports Rising Losses Amid Strong R&D Push and Clinical Advancements

05:02pm, Thursday, Apr 24, 2025

Viking Therapeutics Reports Rising Losses and No Revenue Amid Increased R&D Spending

05:54am, Monday, Aug 26, 2024

Viking Therapeutics Soars: Can VK2735 Create a New High in Metabolic Treatments?

03:37am, Friday, Jul 26, 2024

Eli Lilly's Market Cap Plummet: Is Its Obesity Drug Reign Coming to an End?

08:07am, Friday, Mar 22, 2024

Viking Therapeutics: A New Contender in the Weight Loss Drug Arena and Potential Acquisition Target